跳至主要内容
临床试验/NL-OMON53377
NL-OMON53377招募中3 期

*Randomized controlled prospEctiVe trial comparing extended-release with immediate-release tacrOlimus; reducing calcineurin inhibitor related toxicity in LUng TransplantatION patients* - revolution

Academisch Medisch Centrum0 个研究点目标入组 145 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
145

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • For both the de novo and conversion study:
  • - Participant in Transplanlines biobank study UMCG
  • - Single or bilateral lung transplantation
  • - Age > 18 years
  • - On twice daily tacrolimus with stable trough levels in target range
  • - Written informed consent
  • Additional criteria for:
  • - De novo study: De novo lung transplant patients are recruited before
  • transplantation, and subsequently in all
  • patients put on tacrolimus intravenously. Participants can be randomized when
  • they are on stable daily dosage.
  • - Conversion study:
  • o At least one year after lung transplantation with a stable clinical course
  • o eGFR >30ml/min*1.73m2 calculated with the CKD-EPI formula

排除标准

  • - Administration of mTOR inhibitors; everolimus, sirolimus
  • - Quadruple immunosuppression
  • - Also renal transplant recipient
  • Additional criteria for:
  • - Conversion study
  • o Expected survival < 3 years

研究者

相似试验